Invetso Quality Score — CPHI

Factor Snapshot

Invetso Quality Score

🔴 3.8 (Weak)

Core Drivers

No durable moat or pricing power: The business shows little evidence of protected economics, with weak customer stickiness, limited differentiation, and no structural advantage that would reliably defend margins against global peers.

Capital is not compounding efficiently: Negative returns on invested capital and very low asset productivity indicate that incremental capital has not been translating into value creation, which is the most important long-term weakness.

Balance-sheet conservatism provides only partial support: Low leverage and negative net debt reduce immediate financial strain, but that flexibility does not offset weak earnings quality, poor liquidity, and limited evidence of durable operating improvement.

Key Constraints

Liquidity and cash conversion remain fragile: Very weak current and quick ratios, plus a long cash conversion cycle, leave the company more exposed than stronger peers to working-capital pressure and funding stress.

Growth is not yet proven to be repeatable: The growth profile depends more on execution and niche product demand than on a scalable platform, so the upside case is less durable than for peers with clearer multi-year compounding.

Peer-relative positioning is lagging: Against global pharma peers, the company sits below average on moat, profitability, and resilience, which limits upside asymmetry and makes the investment profile structurally less attractive.

Synthesis

CPHI’s overall investment quality is constrained by a weak economic moat, poor capital efficiency, and limited evidence that reinvestment can compound into durable shareholder value. The main offset is a conservative balance sheet, which reduces immediate distress risk and gives management some room to stabilize operations. However, that strength is not enough to overcome fragile liquidity, weak earnings conversion, and a business model that remains more exposed to price pressure and working-capital swings than stronger global peers. Growth potential exists, but it is execution-dependent rather than structurally advantaged, so the upside path is less reliable than the downside path. Relative to peers, the company is lagging rather than leading, and the current profile suggests more operational repair is needed before the quality case becomes compelling.

Sources

• Company filings (10-K, 10-Q, investor presentations)
• Financial and market data providers
• Public news and industry information